BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Ophthalmology Companies See Global Opportunities for Next-Gen, Non-Invasive Therapies

  Ophthalmology has become a focal point for private equity and venture capitalists in the past 18 months, despite being a small niche in the biopharmaceutical space.

  August 2, 2021

   · 

  5 min read

   · 

  Gail Dutton
• 

  Business

  Ipsen Goes All In on Neuro with $1 Billion+ Deal For Exicure’s Oligonucleotides

  The deal will see Ipsen and Exicure collaborating to research, develop, and commercialize Spherical Nucleic Acids to treat AS and HD.

  August 2, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Study: Servier’s TIBSOVO Prolongs Survival in Untreated IDH1-Mutated AML

  Late-phase trial data show Servier’s TIBSOVO, in conjunction with chemotherapy azacitidine, prolonged event-free survival in adult patients with previously untreated IDH1-mutated acute myeloid leukemia.

  August 2, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Deals

  Aiming Antibodies at Coronaviruses, Adagio Targets $318 Million IPO

  It is offering 17.7 million shares with an expected price between $16 and $18 per share. It will trade on the Nasdaq under the ADGI ticker symbol.

  August 2, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  AbbVie Enjoys Strong Second Quarter as Rinvoq Gears Up to Succeed Humira

  The company saw global net revenue of $13.9 billion during the second quarter, an increase of 33.9%. Sales were primarily driven by its immunology portfolio, which generated $6.12 billion.

  August 2, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Vaxart Scores IND For S-Only Oral Tablet COVID-19 Vaccine Candidate

  The drug, created by Vaxart, has just completed its Phase I trial and had submitted an Investigational New Drug application to move forward.

  August 2, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Pharm Country

  Roivant Invests $200 Million in Immunovant to Advance Autoimmune Disorder Drug Candidate

  The financing will be used to advance the company’s IMVT-1401 candidate across several different autoimmune disorder indications.

  August 2, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Policy

  GOP Presses Lab Leak Investigation as Conflicting Evidence Mounts

  Rep. Michael McCaul issued a third installment today into the origins of the COVID-19 virus and blames the pandemic on a leak from the Wuhan Institute of Virology in China.

  August 2, 2021

   · 

  7 min read

   · 

  Mark Terry
• 

  FDA

  AstraZeneca’s FDA Approval Brings New Hope to the Lupus Community

  Seventeen years after buying global rights, AstraZeneca is finally announcing a win for the lupus community with an FDA approval for Saphnelo.

  August 2, 2021

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Business

  InterVenn, T-knife and Zentara Bolster Missions with New Funding

  The three companies will use their proceeds to support the development of their pipelines through additional business development opportunities.

  August 2, 2021

   · 

  3 min read

   · 

  Alex Keown